Brooke McCormick

AI phenotyping identified cardiovascular and kidney disease as key predictors of rapid fibrosis progression, complications, and higher costs in MASH.

INCA033989 showed responses across type 1 and type 2 mutant calreticulin-positive myelofibrosis, with phase 3 studies underway.

Female newborns were more likely than males to miss vitamin K prophylaxis and hepatitis B birth doses, highlighting sex-based gaps in preventive care.

June author Erin L. Duffy, PhD, MPH, discusses her study showing nonprofit and system-affiliated hospitals provide greater access to translated financial assistance documents.

Families face lasting financial burdens after pediatric cancer, underscoring the need for paid leave, survivorship resources, and financial navigation.

The 2026 State of Dry Eye survey links DED treatment to improved emotional well-being and quality of life amid delays in care and awareness gaps.

Medicare Advantage (MA) beneficiaries had similar optimal cancer treatment use and treatment timing as traditional Medicare (TM), with lower anticipated costs.

Robert Kratzke, MD, discusses how biomarker testing mandates and faster sequencing can improve access to precision lung cancer care.

INCA033989 showed encouraging spleen, anemia, and molecular responses in mutant calreticulin myelofibrosis, suggesting disease-modifying potential.

Financial toxicity in pediatric cancer extends beyond medical bills, affecting treatment adherence, caregivers, and survivors long-term, Cherie Daly, MD, said.

As presented at EHA 2026, AGAVE-201 showed no significant bone health safety signals with axatilimab in chronic graft-versus-host disease (cGVHD).

Expanding on IVBM insights, Robert Kratzke, MD, discusses biomarkers, NGS panels, and treatment options for early-stage NSCLC without actionable alterations.

Erin L. Duffy, PhD, MPH, discusses her findings that nonprofit and system-affiliated hospitals have better multilingual access to financial aid documents.

INCA033989 demonstrated spleen reductions, anemia responses, and molecular improvements in patients with mutant calreticulin–positive myelofibrosis.

The AGAVE-201 analysis found no significant bone health concerns with axatilimab in chronic GVHD, showing stable biomarkers and no increased fractures.

Robert Kratzke, MD, calls for a national biomarker testing mandate, emphasizing that timely genomic testing is essential for precision lung cancer care.

Tec-Dara showed higher MRD-negative CR rates and a 3-year PFS signal in high-risk relapsed/refractory MM, with durability still under longer-term follow-up.

Phase 1 BALLI-01 data showed UCART22 induced remissions with limited severe CRS/ICANS in relapsed/refractory B-cell ALL, supporting phase 2.

The Pediatric Cancer Research Foundation calls for systemic change as pediatric cancer creates long-term financial burdens extending through survivorship.

Senate Democrats introduced a bill to cap out-of-pocket costs at $5000 for traditional Medicare beneficiaries and expand low-income assistance.

Rrisankizumab is the first and only IL-23 inhibitor FDA-approved for children aged 6 and older under 40 kg with plaque psoriasis or psoriatic arthritis.

As discussed at a recent IVBM event, Robert Kratzke, MD, outlines essential biomarkers, NGS panel selection, and next steps when testing is negative for NSCLC.

Nipocalimab improved fatigue by week 2 in patients, supporting its potential as a fast-acting, patient-centered therapy, says Irina Murakhovskaya, MD.

A population-based study linked male sex, Hispanic ethnicity, and select birth and parental factors to increased EOCRC risk.

Since sickle cell disease trial criteria exclude most patients, Julie Kanter, MD, advocated for broader end points and real-world monitoring to improve inclusion.

Selinexor plus ruxolitinib showed greater spleen reductions and an early survival signal in JAK-naive myelofibrosis, Claire Harrison, MD, explained.

The phase 3 SigVie-002 trial showed sigvotatug vedotin missed the OS end point, but the second-line subgroup showed a survival trend and manageable safety.

Current sickle cell disease (SCD) trial eligibility criteria exclude most adults, with only 9.9% meeting inclusion thresholds, Julie Kanter, MD, says.

EHA 2026 highlights include advances in immunotherapy across blood cancers.

Phase 1 BALLI-01 trial results showed promising UCART22 activity in R/R B-cell ALL, with higher remission rates after a manufacturing change.